Biotech & Pharma.T.A, Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A,

BIB 81.96

+3.9%

Dec 3 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: JMarcus who wrote (1437)	12/28/2005 12:31:14 PM
From: Jibacoa	Read Replies (1) of 3722

RGEN Is moving up again on expanding volume, after the comments about RGEN's patent that covers the use of the active compound in Orencia for the treatment of RA, CTLA4-Ig, for cytotoxic T-lymphocyte-associated antigen 4, and specifically mentions the Bristol-Myers FDA application for Orencia. RGEN also owns the rights to a European patent with similar treatment claims. The U.S. patent is in force until 2021, and in Europe until 2013, according to the RGEN's Web site. The stock traded today above its Aug.30 H of 4.18 (it traded at 4.30 from 10.54AM to 11AM )but ithas drifted down to 4.17 at present.<g> bigcharts.marketwatch.com If the stock can close above today's H, it seems it should be able to test the $5 level.<g> bigcharts.marketwatch.com Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next